Key facts
- It has raised $6.8M; the latest was Seed Round ($5.5M) in Oct 2025.
- Notable investors include High-Tech Gründerfonds, Bayern Kapital, Boehringer Ingelheim Venture Fund, Anobis Asset, Incate — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Smartbax
- ·The full record, as it builds
Funding rounds
No funding rounds for Smartbax are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Smartbax
Developer of novel multi-targeted, antibacterial compounds designed to treat bacterial infections and address multiple unexploited targets. The company's products are developed with multiple mechanisms of action by targeting pathogens such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, enabling patients to fight against multiple drug-resistant bacteria.
- Sector
- Healthcare
- HQ
- Munich, Germany
- Founded
- 2021
- Employees
- 4
- Website
- smartbax.de/
- Ownership
- Privately Held (backing)
Smartbax doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Smartbax shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Smartbax in its N-PORT filings yet. We sweep new filings monthly.